Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to adaptive resistance. Therefore, we focused on the mechanisms underlying adapt...

Descripción completa

Detalles Bibliográficos
Autores principales: Katayama, Yuki, Yamada, Tadaaki, Tanimura, Keiko, Tokuda, Shinsaku, Morimoto, Kenji, Hirai, Soichi, Matsui, Yohei, Nakamura, Ryota, Ishida, Masaki, Kawachi, Hayato, Yoneda, Kazue, Hosoya, Kazutaka, Tsuji, Takahiro, Ozasa, Hiroaki, Yoshimura, Akihiro, Iwasaku, Masahiro, Kim, Young Hak, Horinaka, Mano, Sakai, Toshiyuki, Utsumi, Takahiro, Shiotsu, Shinsuke, Takeda, Takayuki, Katayama, Ryohei, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879975/
https://www.ncbi.nlm.nih.gov/pubmed/36702855
http://dx.doi.org/10.1038/s41698-023-00350-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879975/
https://www.ncbi.nlm.nih.gov/pubmed/36702855
http://dx.doi.org/10.1038/s41698-023-00350-7

Ejemplares similares